INFI Annual FCF
-$42.45 M
-$1.82 M-4.48%
31 December 2022
Summary:
As of January 21, 2025, INFI annual free cash flow is -$42.45 million, with the most recent change of -$1.82 million (-4.48%) on December 31, 2022. During the last 3 years, it has risen by +$1.41 million (+3.21%).INFI Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI Quarterly FCF
-$8.01 M
+$4.57 M+36.33%
30 June 2023
Summary:
As of January 21, 2025, INFI quarterly free cash flow is -$8.01 million, with the most recent change of +$4.57 million (+36.33%) on June 30, 2023. Over the past year, it has increased by +$2.59 million (+24.43%).INFI Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI TTM FCF
-$38.88 M
+$2.59 M+6.24%
30 June 2023
Summary:
As of January 21, 2025, INFI TTM free cash flow is -$38.88 million, with the most recent change of +$2.59 million (+6.24%) on June 30, 2023. Over the past year, it has increased by +$2.85 million (+6.84%).INFI TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4.5% | +24.4% | +6.8% |
| 3 y3 years | +3.2% | -5.4% | +3.2% |
| 5 y5 years | -15.5% | -65.9% | +11.3% |
INFI Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -136.5% | -103.4% | -130.5% |
Infinity Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$8.01 M(-36.3%) | -$38.88 M(-6.2%) |
| Mar 2023 | - | -$12.58 M(+41.3%) | -$41.47 M(-2.3%) |
| Dec 2022 | -$42.45 M(+4.5%) | -$8.90 M(-5.3%) | -$42.45 M(-1.9%) |
| Sept 2022 | - | -$9.40 M(-11.3%) | -$43.27 M(+3.7%) |
| June 2022 | - | -$10.60 M(-21.8%) | -$41.74 M(+2.5%) |
| Mar 2022 | - | -$13.55 M(+39.5%) | -$40.71 M(+0.2%) |
| Dec 2021 | -$40.63 M(+13.5%) | -$9.72 M(+23.4%) | -$40.63 M(+3.1%) |
| Sept 2021 | - | -$7.87 M(-17.7%) | -$39.42 M(-0.0%) |
| June 2021 | - | -$9.57 M(-29.0%) | -$39.43 M(+5.3%) |
| Mar 2021 | - | -$13.47 M(+58.3%) | -$37.46 M(+4.7%) |
| Dec 2020 | -$35.78 M(-18.4%) | -$8.51 M(+7.9%) | -$35.78 M(-3.1%) |
| Sept 2020 | - | -$7.88 M(+3.8%) | -$36.91 M(-8.1%) |
| June 2020 | - | -$7.59 M(-35.6%) | -$40.19 M(+0.6%) |
| Mar 2020 | - | -$11.79 M(+22.3%) | -$39.94 M(-8.9%) |
| Dec 2019 | -$43.86 M(+830.4%) | -$9.64 M(-13.6%) | -$43.86 M(+145.6%) |
| Sept 2019 | - | -$11.15 M(+51.7%) | -$17.86 M(+30.4%) |
| June 2019 | - | -$7.35 M(-53.2%) | -$13.69 M(+22.6%) |
| Mar 2019 | - | -$15.71 M(-196.0%) | -$11.17 M(+136.9%) |
| Dec 2018 | -$4.71 M(-87.2%) | $16.36 M(-334.0%) | -$4.71 M(-76.3%) |
| Sept 2018 | - | -$6.99 M(+44.9%) | -$19.88 M(-17.0%) |
| June 2018 | - | -$4.83 M(-47.9%) | -$23.95 M(-16.9%) |
| Mar 2018 | - | -$9.26 M(-877.1%) | -$28.83 M(-21.5%) |
| Dec 2017 | -$36.75 M(-76.3%) | $1.19 M(-110.8%) | -$36.75 M(-37.6%) |
| Sept 2017 | - | -$11.06 M(+14.0%) | -$58.91 M(-29.0%) |
| June 2017 | - | -$9.71 M(-43.5%) | -$82.96 M(-30.9%) |
| Mar 2017 | - | -$17.18 M(-18.1%) | -$120.05 M(-22.6%) |
| Dec 2016 | -$155.02 M(+72.1%) | -$20.97 M(-40.3%) | -$155.02 M(+196.5%) |
| Sept 2016 | - | -$35.11 M(-25.0%) | -$52.29 M(-2.3%) |
| June 2016 | - | -$46.80 M(-10.3%) | -$53.55 M(+29.2%) |
| Mar 2016 | - | -$52.14 M(-163.8%) | -$41.45 M(-54.0%) |
| Dec 2015 | -$90.08 M(-177.4%) | $81.76 M(-324.8%) | -$90.08 M(-59.0%) |
| Sept 2015 | - | -$36.37 M(+4.8%) | -$219.81 M(-501.9%) |
| June 2015 | - | -$34.70 M(-65.6%) | $54.70 M(-7.8%) |
| Mar 2015 | - | -$100.77 M(+110.0%) | $59.31 M(-49.0%) |
| Dec 2014 | $116.35 M(-200.6%) | -$47.98 M(-120.1%) | $116.35 M(-8.7%) |
| Sept 2014 | - | $238.15 M(-891.6%) | $127.45 M(-192.7%) |
| June 2014 | - | -$30.08 M(-31.2%) | -$137.46 M(+2.7%) |
| Mar 2014 | - | -$43.73 M(+18.6%) | -$133.81 M(+15.7%) |
| Dec 2013 | -$115.66 M(+42.0%) | -$36.88 M(+37.8%) | -$115.66 M(+0.1%) |
| Sept 2013 | - | -$26.77 M(+1.3%) | -$115.50 M(-3.3%) |
| June 2013 | - | -$26.43 M(+3.3%) | -$119.48 M(+25.0%) |
| Mar 2013 | - | -$25.59 M(-30.3%) | -$95.57 M(+17.4%) |
| Dec 2012 | -$81.44 M(+135.0%) | -$36.72 M(+19.5%) | -$81.44 M(+50.8%) |
| Sept 2012 | - | -$30.74 M(+1116.9%) | -$53.99 M(+77.8%) |
| June 2012 | - | -$2.53 M(-77.9%) | -$30.36 M(-17.1%) |
| Mar 2012 | - | -$11.45 M(+23.5%) | -$36.63 M(+5.7%) |
| Dec 2011 | -$34.65 M | -$9.27 M(+30.4%) | -$34.65 M(+1.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$7.11 M(-19.2%) | -$34.28 M(-6.9%) |
| June 2011 | - | -$8.80 M(-7.1%) | -$36.83 M(+7.8%) |
| Mar 2011 | - | -$9.47 M(+6.4%) | -$34.15 M(+19.7%) |
| Dec 2010 | -$28.53 M(+291.7%) | -$8.90 M(-7.8%) | -$28.53 M(-1.1%) |
| Sept 2010 | - | -$9.66 M(+57.8%) | -$28.85 M(+0.7%) |
| June 2010 | - | -$6.12 M(+58.9%) | -$28.65 M(+11.8%) |
| Mar 2010 | - | -$3.85 M(-58.2%) | -$25.62 M(+251.7%) |
| Dec 2009 | -$7.28 M(-38.3%) | -$9.22 M(-2.5%) | -$7.28 M(-128.9%) |
| Sept 2009 | - | -$9.46 M(+206.0%) | $25.24 M(+22.1%) |
| June 2009 | - | -$3.09 M(-121.3%) | $20.66 M(+57.3%) |
| Mar 2009 | - | $14.48 M(-37.8%) | $13.14 M(-211.2%) |
| Dec 2008 | -$11.81 M(-222.1%) | $23.30 M(-266.1%) | -$11.81 M(-68.8%) |
| Sept 2008 | - | -$14.03 M(+32.1%) | -$37.87 M(+22.8%) |
| June 2008 | - | -$10.62 M(+1.5%) | -$30.85 M(+16.1%) |
| Mar 2008 | - | -$10.47 M(+279.4%) | -$26.57 M(-374.5%) |
| Dec 2007 | $9.68 M(+11.1%) | -$2.76 M(-60.6%) | $9.68 M(+122.4%) |
| Sept 2007 | - | -$7.01 M(+10.6%) | $4.35 M(-87.3%) |
| June 2007 | - | -$6.33 M(-124.6%) | $34.21 M(+12.6%) |
| Mar 2007 | - | $25.78 M(-418.8%) | $30.39 M(+248.9%) |
| Dec 2006 | $8.71 M(-128.8%) | -$8.09 M(-135.4%) | $8.71 M(-6.9%) |
| Sept 2006 | - | $22.85 M(-325.0%) | $9.35 M(-123.4%) |
| June 2006 | - | -$10.15 M(-347.7%) | -$39.92 M(+26.1%) |
| Mar 2006 | - | $4.10 M(-155.1%) | -$31.67 M(+4.7%) |
| Dec 2005 | -$30.24 M(-8.2%) | -$7.44 M(-71.8%) | -$30.24 M(-47.2%) |
| Sept 2005 | - | -$26.43 M(+1290.2%) | -$57.24 M(+92.2%) |
| June 2005 | - | -$1.90 M(-134.4%) | -$29.79 M(+8.7%) |
| Mar 2005 | - | $5.53 M(-116.1%) | -$27.40 M(-16.8%) |
| Dec 2004 | -$32.93 M(-618.8%) | -$34.44 M(-3472.7%) | -$32.93 M(-877.3%) |
| Sept 2004 | - | $1.02 M(+111.5%) | $4.24 M(+40.2%) |
| June 2004 | - | $482.80 K(+9556.0%) | $3.02 M(-16.9%) |
| Mar 2004 | - | $5000.00(-99.8%) | $3.64 M(-42.7%) |
| Dec 2003 | $6.35 M(-231.0%) | $2.73 M(-1512.5%) | $6.35 M(+49.6%) |
| Sept 2003 | - | -$193.10 K(-117.6%) | $4.24 M(+382.3%) |
| June 2003 | - | $1.10 M(-59.5%) | $879.80 K(-155.1%) |
| Mar 2003 | - | $2.71 M(+335.5%) | -$1.60 M(-67.1%) |
| Dec 2002 | -$4.84 M(-77.2%) | $623.40 K(-117.5%) | -$4.84 M(-79.2%) |
| Sept 2002 | - | -$3.56 M(+158.2%) | -$23.26 M(+38.1%) |
| June 2002 | - | -$1.38 M(+157.9%) | -$16.85 M(-15.6%) |
| Mar 2002 | - | -$534.00 K(-97.0%) | -$19.96 M(-5.9%) |
| Dec 2001 | -$21.23 M(+606.6%) | -$17.79 M(-722.4%) | -$21.22 M(+493.4%) |
| Sept 2001 | - | $2.86 M(-163.6%) | -$3.58 M(-38.3%) |
| June 2001 | - | -$4.50 M(+150.5%) | -$5.80 M(+133.4%) |
| Mar 2001 | - | -$1.79 M(+1123.8%) | -$2.48 M(-17.3%) |
| Dec 2000 | -$3.00 M(-56.1%) | -$146.60 K(-123.0%) | -$3.00 M(+5.1%) |
| Sept 2000 | - | $638.70 K(-154.0%) | -$2.86 M(-18.3%) |
| June 2000 | - | -$1.18 M(-48.9%) | -$3.50 M(+51.1%) |
| Mar 2000 | - | -$2.31 M | -$2.31 M |
| Dec 1999 | -$6.85 M | - | - |
FAQ
- What is Infinity Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals annual FCF year-on-year change?
- What is Infinity Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals quarterly FCF year-on-year change?
- What is Infinity Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals TTM FCF year-on-year change?
What is Infinity Pharmaceuticals annual free cash flow?
The current annual FCF of INFI is -$42.45 M
What is the all time high annual FCF for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high annual free cash flow is $116.35 M
What is Infinity Pharmaceuticals annual FCF year-on-year change?
Over the past year, INFI annual free cash flow has changed by -$1.82 M (-4.48%)
What is Infinity Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of INFI is -$8.01 M
What is the all time high quarterly FCF for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high quarterly free cash flow is $238.15 M
What is Infinity Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, INFI quarterly free cash flow has changed by +$2.59 M (+24.43%)
What is Infinity Pharmaceuticals TTM free cash flow?
The current TTM FCF of INFI is -$38.88 M
What is the all time high TTM FCF for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high TTM free cash flow is $127.45 M
What is Infinity Pharmaceuticals TTM FCF year-on-year change?
Over the past year, INFI TTM free cash flow has changed by +$2.85 M (+6.84%)